Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Ixiaro regulatory update

July 29, 2013 7:00 AM UTC

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The product is marketed as Ixiaro in Canada, Europe, Hong Kong, Israel, Singapore and the U.S., where it has Orphan Drug status, and as Jespect in Australia and New Zealand. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article